首页> 外文OA文献 >N-(INDAZOLYL)BENZAMIDO DERIVATIVES AS CDK1 INHIBITORS: DESIGN, SYNTHESIS, BIOLOGICAL ACTIVITY, AND MOLECULAR DOCKING STUDIES
【2h】

N-(INDAZOLYL)BENZAMIDO DERIVATIVES AS CDK1 INHIBITORS: DESIGN, SYNTHESIS, BIOLOGICAL ACTIVITY, AND MOLECULAR DOCKING STUDIES

机译:N-(吲哚基)苯甲酰胺衍生物作为CDK1抑制剂:设计,合成,生物活性和分子对接研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

A series of N-1H-indazole-1-carboxamides have been synthesized and their effects on both CDK1/cyclin B and K-562 (human chronic myelogenus leukemia) cell line were evaluated. Using a computational model we have observed that all the most active compound 9e,f,i-n exhibited the same binding mode of Purvanalol A in the ATP-binding cleft. Although they were able to moderately inhibit the leukemic cell line K-562, and to show inhibitory activity against the Cdc2-Cyclin B kinase in the low micromolar range, they resulted non cytotoxic against HuDe (IZSL), primary cell cultures from human derm. These preliminary results are quite encouraging in view of the low toxicity showed by the above mentioned compounds.
机译:已合成了一系列N-1H-吲唑-1-羧酰胺,并评估了它们对CDK1 / cyclin B和K-562(人类慢性粒细胞白血病)细胞系的作用。使用计算模型,我们已经观察到,在ATP结合裂隙中,所有活性最高的化合物9e,f,i-n表现出相同的Purvanalol A结合模式。尽管它们能够适度抑制白血病细胞系K-562,并在低微摩尔范围内显示出对Cdc2-细胞周期蛋白B激酶的抑制活性,但它们对人类皮肤的原代细胞培养物HuDe(IZSL)产生了无细胞毒性。考虑到上述化合物显示的低毒性,这些初步结果令人鼓舞。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号